Skip to main content
SENATE 854119th CongressPlaced on Senate Legislative Calendar under General Orders. Calendar No. 164.

Risky Research Review Act

Last Action
9/17/2025

Actions

  • 2025-09-17Placed on Senate Legislative Calendar under General Orders. Calendar No. 164.
  • 2025-09-17Committee on Homeland Security and Governmental Affairs. Reported by Senator Paul without amendment. Without written report.
  • 2025-09-17Committee on Homeland Security and Governmental Affairs. Reported by Senator Paul without amendment. Without written report.
  • 2025-07-30Committee on Homeland Security and Governmental Affairs. Ordered to be reported without amendment favorably.
  • 2025-03-05Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
  • 2025-03-05Introduced in Senate

CRS Summary

As of 2025-03-05 (00)

Risky Research Review Act

This bill establishes the Life Sciences Research Security Board to oversee the award of federal funding for high-risk life sciences research. High-risk life sciences research means the study of an organism, virus, or related product that could be misapplied to pose a significant threat to the public or could enhance the transmissibility or virulence of certain high-risk pathogens (e.g., Ebola).

Specifically, the bill establishes the board as an independent agency that must review proposed high-risk life sciences research, determine whether a federal agency may award funding for the research, and determine minimum required controls for funded research. Entities that are seeking federal funding must attest to whether their research is high-risk life sciences research. Agencies must certify the validity of these attestations and submit proposed high-risk life sciences research to the board. Agencies must also notify the board of intended awards for other life sciences research for potential review. 

In making its determinations, the board must consider specified factors, including whether the benefits of the research outweigh the risks. The bill prohibits agencies from awarding federal funding for high-risk life sciences research without approval of the board or for life sciences research currently under board review. The board may also review awards that were made before the bill’s enactment.

Entities that fail to properly attest to the nature of their research may lose their eligibility for funding. Additionally, agency employees who fail to comply with the bill's requirements are subject to disciplinary action.

Cosponsors (1)

  • Gary Peters (D-MI)

Subjects

  • Accounting and auditing
  • Advisory bodies
  • Biological and life sciences
  • Congressional oversight
  • Employee performance
  • Federal officials
  • Government employee pay, benefits, personnel management
  • Government ethics and transparency, public corruption
  • Government information and archives
  • Government studies and investigations
  • Infectious and parasitic diseases
  • Public contracts and procurement
  • Research administration and funding
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.